Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma, including any of the following:
• •* B-cell diffuse large cell variant
• •* Immunoblastic
• •* Mediastinal (thymic) large cell
• •* T-cell/histiocyte-rich
• •* Anaplastic large B-cell
• •* Intravascular large B-cell
• •* Lymphomatoid granulomatosis
• •Relapsed or refractory disease after at least 1 prior chemotherapy regimen and requires further treatment
• •* Relapsed disease, defined as the following:
• •* Appearance of any new lesion OR increase of at least 50% in the size of a previously involved site
• •* 50% increase in greatest diameter of any previously identified node greater than 1 cm in the short axis OR in the sum of the perpendicular diameter (SPD) of more than 1 node
• •* Progressive disease, defined as the following:
• •* 50% increase from nadir in the SPD of any previously identified abnormal node
• •* Appearance of any new lesion during or at the end of therapy
• •CD20-positive disease by immunohistochemistry
• •Bidimensionally measurable disease
• •* At least 1 lesion at least 2.0 cm by CT scan
• •Less than 25% bone marrow involvement by lymphoma
• •No transformed lymphoma from indolent to aggressive
• •No HIV- or AIDS-related lymphoma
• •No hypocellular bone marrow
• •No marked reduction in bone marrow precursors of 1 or more cell lines (e.g., granulocytic, megakaryocytic, or erythroid)
• •No CNS lymphoma
• •Ineligible for myeloablative therapy OR refused transplantation
• •Ineligible for any other open yttrium Y 90 ibritumomab tiuxetan investigational protocols
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •WHO 0-2
• •Life expectancy
• •At least 3 months
• •Hematopoietic
• •Absolute neutrophil count at least 1,500/mm\^3
• •Lymphocyte count no greater than 5,000/mm\^3 (for patients with small lymphocytic lymphoma)
• •Platelet count at least 100,000/mm\^3
• •Hepatic
• •Bilirubin no greater than 2.0 mg/dL
• •Renal
• •Creatinine no greater than 2.0 mg/dL
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 1 year after study participation
• •No concurrent serious nonmalignant disease or infection that would preclude study participation
• •No human antimurine antibody reactivity
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •See Disease Characteristics
• •No prior autologous bone marrow transplantation
• •No prior peripheral blood stem cell rescue
• •No prior failed stem cell collection
• •Prior rituximab within the past 90 days allowed provided patient has fludeoxyglucose-avid disease that is also indium In 111 ibritumomab tiuxetan-avid disease in at least 1 lesion
• •More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• •Chemotherapy
• •See Disease Characteristics
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •No prior radioimmunotherapy
• •No prior external beam radiotherapy (involved field or regional) to more than 25% of active bone marrow
• •Surgery
• •More than 4 weeks since prior major surgery (except diagnostic surgery)
• •Other
• •Recovered from all prior therapy
• •More than 4 weeks since prior therapy for lymphoma
• •More than 8 weeks since prior phase II investigational drugs
• •No other concurrent antineoplastic therapy